Devyser has secured a tender for its NGS product, Devyser Thalassemia, a screening test for diagnosing thalassemia. The tender was awarded by Istituto Giannina Gaslini in Genoa and is valid for two years. The value of the transaction amounted to approximately 3.5 million SEK (USD 3.3 million).
The partnership entails a two-year supply agreement for Devyser’s thalassemia NGS product, allowing the company to penetrate the Italian market. The company claims that the test can be used in any laboratory running genetic testing or large-scale mutation screening.
Sweden-based Devyser Diagnostics specializes in the development, manufacture, and sale of genetic testing kits. The company focuses on providing diagnostic solutions for complex DNA testing used in areas such as oncology, hematology, reproductive health, cystic fibrosis, cardiovascular diseases, and post-transplantation monitoring.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.